EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
ShenCun Fang
Meta Tag
Speaker ShenCun Fang
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
WCLC 2023
neoadjuvant therapy
unresectable stage IIIA-IVA
EGFR mutations
overall response rate
minimally invasive surgery
pathological complete response
safety profile
Powered By